永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06978 永泰生物-B

收市竞价 02-27 16:04:56

2.740

+0.020

+0.74%

最高2.780	最低2.720	成交量27.84万
今开2.770	昨收2.720	日振幅2.21%
总市值16.93亿	流通市值16.93亿	总股本6.18亿
成交额76.80万	换手率0.05%	流通股本6.18亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06978","market":"HK","secType":"STK","nameCN":"永泰生物-B","latestPrice":2.74,"timestamp":1772179273672,"preClose":2.72,"halted":0,"volume":278400,"delay":0,"changeRate":0.007352941176470594,"floatShares":618000000,"shares":618000000,"eps":-0.363229,"marketStatus":"收市竞价","change":0.02,"latestTime":"02-27 16:04:56","open":2.77,"high":2.78,"low":2.72,"amount":767950,"amplitude":0.022059,"askPrice":2.74,"askSize":3000,"bidPrice":2.74,"bidSize":12000,"shortable":0,"etf":0,"ttmEps":-0.397,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1772179800000},"marketStatusCode":4,"adr":0,"listingDate":1594310400000,"exchange":"SEHK","adjPreClose":2.72,"openAndCloseTimeList":[[1772155800000,1772164800000],[1772168400000,1772179200000]],"volumeRatio":1.490196,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06978","defaultTab":"news","newsList":[{"id":"1128119023","title":"港股创新药概念股走强！药明合联涨超7%，云顶新耀、再鼎医药涨近6%","url":"https://stock-news.laohu8.com/highlight/detail?id=1128119023","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128119023?lang=zh_cn&edition=full","pubTime":"2026-02-27 09:40","pubTimestamp":1772156400,"startTime":"0","endTime":"0","summary":"2月27日，港股创新药概念股走强，$药明合联(02268)$涨超7%，$云顶新耀(01952)$、$再鼎医药(ZLAB)$涨近6%，$康方生物(09926)$、$药明生物(02269)$涨超4%，$歌礼制药-B(01672)$涨超3%。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK4548","06978","VXUS","01952","BK1141","159992","02268","BK1588","BK1161","VT","BK4139","BK4526","LU2488822045.USD","ZLAB","BK4588","09688","BK1574","BK4531","SG9999014674.SGD","BK4585"],"gpt_icon":0},{"id":"2614073003","title":"石药集团一项创新药研究成果入选2026年第10届国际头颈部肿瘤创新大会(ICHNO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2614073003","media":"石药集团","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614073003?lang=zh_cn&edition=full","pubTime":"2026-02-27 08:15","pubTimestamp":1772151355,"startTime":"0","endTime":"0","summary":"2026年3月19日至21日，第10届国际头颈部肿瘤创新大会将在西班牙塞维利亚召开，ICHNO由欧洲放射治疗与肿瘤学学会、欧洲头颈学会和欧洲肿瘤内科学会联合主办，是宣传推动多学科头颈部肿瘤学发展的国际盛会。本临床研究结果显示SYS6043有望为晚期鼻咽癌提供一种新的治疗选择。SYS6043作为新一代B7-H3靶点ADC，此次在ICHNO大会上的亮眼数据表明其在鼻咽癌领域具有良好的抗肿瘤活性和持续缓解的能力，有望为晚期鼻咽癌后线治疗带来新的突破。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026022708273197a73604&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026022708273197a73604&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BZ08YR35.GBP","LU1807302812.USD","06978","LU1226288170.HKD","LU1993786604.SGD","IE00B5MMRT66.SGD","LU1152091754.HKD","LU1960683339.HKD","IE00BZ08YS42.EUR","LU0072913022.USD","LU0315179316.USD","LU1226288253.USD","BK1515","LU0501845795.SGD","IE0008368742.USD","HK0000165453.HKD","BK1191","LU1328277881.USD","LU1226287792.SGD","LU0880133367.SGD","LU1226287529.USD","LU1226287875.USD","BK1521","SG9999004220.SGD","IE00B543WZ88.USD","BK1161","LU1951186391.HKD","LU1008478684.HKD","BK1574","LU0140636845.USD","LU1152091168.USD","IE0008369823.USD","01093","LU0067412154.USD","LU1813983027.USD","IE00B031HY20.USD","LU0314109678.HKD","LU2039709279.SGD","IE00BZ08YT58.USD","LU0326950275.SGD"],"gpt_icon":0},{"id":"2614091923","title":"盈喜预告接连发布：BD成估值新锚，药企加速跨越生死线","url":"https://stock-news.laohu8.com/highlight/detail?id=2614091923","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614091923?lang=zh_cn&edition=full","pubTime":"2026-02-26 14:29","pubTimestamp":1772087394,"startTime":"0","endTime":"0","summary":"2月25日，先声药业发布盈喜预告。预告显示，2025财政年度公司预计录得收入约人民币77亿至78亿元，同比增长16.0%至17.6%；而归属于公司权益股东的利润更是有望达到人民币13亿至14亿元，同比增幅高达80.1%至93.9%。在医药行业整体仍在调整期中艰难跋涉的背景下，这份接近翻倍的利润增长答卷显得尤为耀眼。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602263655228925.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602263655228925.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BMS","06978","BK1583","BK1191","BK1574","02096","BK1161","02615"],"gpt_icon":0},{"id":"2614635990","title":"【ETF动向】2月25日银华中证创新药产业ETF基金涨0.72%，份额减少1.22亿份","url":"https://stock-news.laohu8.com/highlight/detail?id=2614635990","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614635990?lang=zh_cn&edition=full","pubTime":"2026-02-26 08:03","pubTimestamp":1772064210,"startTime":"0","endTime":"0","summary":"证券之星消息，2月25日，银华中证创新药产业ETF基金（159992）涨0.72%，成交额4.89亿元。当日份额减少了1.22亿份，最新份额为179.95亿份，近20个交易日份额增加9.98亿份。当日资金净流入1799.09万元（资金流向是当日计算的资产净值和上一交易日计算的资产净值相减得出的），最新资产净值计算值为150.08亿元。银华中证创新药产业ETF基金跟踪标的为中证创新药产业指数，成立（2020-03-20）以来超额回报为-7.53%，近一个月超额回报为-0.02%，管理人为银华基金公司，基金经理为马君 王帅。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022600003617.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","06978","159992","BK1574"],"gpt_icon":0},{"id":"2614315660","title":"中国创新药“出海”势头强劲 年内海外授权总金额突破530亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2614315660","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614315660?lang=zh_cn&edition=full","pubTime":"2026-02-26 00:03","pubTimestamp":1772035438,"startTime":"0","endTime":"0","summary":"2026年，中国创新药对外BD交易（商务拓展交易）持续升温、势头强劲。医药魔方NextPharma数据库显示，截至2月25日，年内中国创新药已发生44起对外授权（license-out）交易事件，首付款约为31.23亿美元，总金额达532.76亿美元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602263654413723.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","159992","06978","BK1574"],"gpt_icon":0},{"id":"2614036369","title":"永泰生物-B(06978)向浦发银行认购5000万元结构性存款产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2614036369","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614036369?lang=zh_cn&edition=full","pubTime":"2026-02-25 23:00","pubTimestamp":1772031618,"startTime":"0","endTime":"0","summary":"智通财经APP讯，永泰生物-B(06978)发布公告，公司于2026年2月25日向浦发银行认购结构性存款产品，投资价值为人民币5000万元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1407333.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06978","BK0278","BK1161","SGXZ49509284.SGD","BK0015","LU1934453819.USD","SGXZ81163826.USD","LU0469268626.HKD","BK0028","BK0187","LU1979443071.USD","BK0012","BK0188","LU1808992512.USD","BK1574","BK0201","600000","BK0086","BK0183"],"gpt_icon":0},{"id":"2614092437","title":"动保业务颓势难改，申联生物跨界掘金人用创新药，续亏之下双主业谋变待考","url":"https://stock-news.laohu8.com/highlight/detail?id=2614092437","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614092437?lang=zh_cn&edition=full","pubTime":"2026-02-25 16:23","pubTimestamp":1772007786,"startTime":"0","endTime":"0","summary":"标的世之源手握三款分别针对病毒感染和过敏免疫领域的在研创新药，申联生物试图通过收购切入人用创新药赛道，剑指“人用药品+ 动物保健”双主业发展格局。收购完成后，申联生物将形成“人用药品”与“动物保健”双主业协同发展的新格局。收购世之源，申联生物寄予一定厚望，但也面临重重挑战。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260225/32026374.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["06978","BK1574","BK1161","BK0239","688098","159992"],"gpt_icon":0},{"id":"2614755776","title":"市值不到80亿元的创新药企前沿生物，股价突然暴跌，成A股跌幅最大个股","url":"https://stock-news.laohu8.com/highlight/detail?id=2614755776","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614755776?lang=zh_cn&edition=full","pubTime":"2026-02-25 11:26","pubTimestamp":1771989960,"startTime":"0","endTime":"0","summary":"公司才达成一笔超10亿美元的授权交易。2月25日，科创板创新药企前沿生物股价开盘后直泻，截至上午10点55分之际，股价跌幅达到15.59%，成为A股跌幅第一大个股，市值报78.06亿元。前沿生物股价突然暴跌，让一些投资者有些措手不及。就在前日，即2月23日，前沿生物才刚刚宣布，与全球生物制药企业葛兰素史克达成一项独家授权许可协议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2026-02-25/doc-inhnyyvq8063878.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-02-25/doc-inhnyyvq8063878.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","159982","BK1161","06978","688221","399300","BK0239","159992"],"gpt_icon":0},{"id":"2614727781","title":"恒生科技短线超卖，关注覆盖创新药的港股通科技ETF（159101）","url":"https://stock-news.laohu8.com/highlight/detail?id=2614727781","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614727781?lang=zh_cn&edition=full","pubTime":"2026-02-25 09:07","pubTimestamp":1771981674,"startTime":"0","endTime":"0","summary":"去年10月以来，恒生科技在内的港股科技指数持续回调，源于市场对流动性、权重股业绩、AI叙事等多方面担忧。投资工具方面，近期可关注港股通科技基金，其跟踪国证港股通科技指数，相较于恒生科技指数，国证港股通科技指数多纳入了盈利预期强劲的创新药板块。场外基金投资者可以关注华夏国证港股通科技ETF联接C。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/SS2026022500006448.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["03033","BK1161","159992","159101","06978","BK1574","159740","515000","BK1610"],"gpt_icon":0},{"id":"2613105057","title":"创新药向上还是向下：BD交易爆发、大摩持续唱多 板块仍处调整期","url":"https://stock-news.laohu8.com/highlight/detail?id=2613105057","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613105057?lang=zh_cn&edition=full","pubTime":"2026-02-24 22:26","pubTimestamp":1771943203,"startTime":"0","endTime":"0","summary":"2026年，我国创新药出海延续高景气度，最近两天先为达、前沿生物及和铂医药接连达成三笔BD（商务拓展）交易。医药魔方NextPharma数据库显示，截至2月15日（春节假期期间暂未新增交易事件），中国创新药已发生39起license-out（对外授权）交易事件，首付款约29.53亿美元，总金额超490亿美元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602243653031028.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602243653031028.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0320765646.SGD","LU0528227936.USD","LU1162221912.USD","LU1791710582.SGD","BK1574","IE00BKVL7J92.USD","LU2133065610.SGD","LU0314104364.USD","LU0795875086.SGD","LU0234570918.USD","BK4534","159992","LU0106831901.USD","LU0882574139.USD","BK1161","LU1668664300.SGD","LU0098860793.USD","LU1791710400.SGD","LU0795875169.SGD","LU2028103732.USD","LU1074936037.SGD","BK4588","LU0106261372.USD","LU0557290698.USD","LU2023251221.USD","LU2347655156.SGD","LU1989772840.SGD","LU0006306889.USD","BK4516","LU1244550221.USD","LU0158827948.USD","LU0912757837.SGD","LU1732800096.USD","LU2089283258.USD","LU0267386448.USD","BK4585","LU2357305700.SGD","LU0225283273.USD","LU1720051108.HKD","LU1363072403.SGD","LU0158827781.USD","LU1720051017.SGD","LU2271345857.HKD","LU0971096721.USD","BK4581","LU1548497426.USD","06978","BK4127","LU2089284900.SGD","LU1244550494.USD"],"gpt_icon":0},{"id":"2614747108","title":"节后A股首个交易日 年轻人的“药理财”表现如何？","url":"https://stock-news.laohu8.com/highlight/detail?id=2614747108","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614747108?lang=zh_cn&edition=full","pubTime":"2026-02-24 20:38","pubTimestamp":1771936713,"startTime":"0","endTime":"0","summary":"2月24日，A股节后首个交易日，医药商业板块和医疗器械板块领涨，分别上涨1.28%和0.66%，化学制药上涨0.50%，拉长时间线看，创新药、CXO、高端医疗器械等板块正加速复苏。这一表现，也将创下公司上市以来归母净利润的历史新高。昔日“疫苗之王”智飞生物，自上市以来首次年报亏损。目前，智飞生物的代理产品收入占比高达90%，其代理的默沙东HPV疫苗业务缩水，是其业绩下滑的关键因素。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224211742a71a1893&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224211742a71a1893&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06127","02359","BK1141","06978","LU0320764599.SGD","BK1574","LU0708995583.HKD","09969","BK1161","02315","LU2045819591.USD","03347","09995","LU2125910500.SGD","LU0052750758.USD","BK1576","LU1046422090.SGD","01877","LU2242644610.SGD","BK1583"],"gpt_icon":0},{"id":"2613871794","title":"康哲药业(00867)：创新药磷酸芦可替尼乳膏增加特应性皮炎(AD)适应症中国上市许可申请获受理并获纳入优先审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2613871794","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613871794?lang=zh_cn&edition=full","pubTime":"2026-02-24 17:49","pubTimestamp":1771926559,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康哲药业 发布公告，旗下德镁医药有限公司已于2026年2月24日获得中国国家药品监督管理局受理磷酸芦可替尼乳膏轻中度特应性皮炎的新药上市许可申请。且该项NDA因“符合儿童生理特征的儿童用药品新品种、剂型和规格”，已获得NMPA药品审评中心批准纳入优先审评品种名单，有望加快产品AD适应症上市审评进程。此次增加AD适应症NDA获受理，是产品向多治疗领域拓展的关键里程碑。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1406728.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06978","IE00BYV24P56.USD","IE00BMCWC346.EUR","BK1574","SG9999015986.USD","159992","SG9999015978.USD","AD","BK1191","BK4132","IE00BGHQDM52.EUR","BK1161","BK1593","SG9999015945.SGD","LU2488822045.USD","IE00BVYPNQ40.USD","00867","SG9999004220.SGD","SG9999015952.SGD","IE00BVYPNP33.GBP"],"gpt_icon":0},{"id":"2613794846","title":"申联生物最新公告：拟2.37亿元收购世之源控股权并开展创新药业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2613794846","media":"证券之星","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613794846?lang=zh_cn&edition=full","pubTime":"2026-02-24 17:40","pubTimestamp":1771926009,"startTime":"0","endTime":"0","summary":"申联生物(688098.SH)公告称，公司拟使用2.37亿元自有资金及自筹资金，通过全资子公司上海本天成生物医药有限公司以股权转让及增资方式取得扬州世之源生物科技有限责任公司的控股权。交易完成后，本天成及其一致行动人将合计持有世之源51%的股权，世之源成为公司的控股孙公司，纳入上市公司合并报表范围。公司将全面开展创新药业务，形成“人用药品”与“动物保健”双主业协同发展的新格局。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022400033461.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688098","BK1574","BK0239","06978","BK1161","159992"],"gpt_icon":0},{"id":"2613862796","title":"恒瑞医药(600276.SH)：1类创新药SHR-1918注射液药品上市许可申请获受理并纳入优先审评程序","url":"https://stock-news.laohu8.com/highlight/detail?id=2613862796","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613862796?lang=zh_cn&edition=full","pubTime":"2026-02-24 16:44","pubTimestamp":1771922674,"startTime":"0","endTime":"0","summary":"智通财经APP讯， 恒瑞医药 发布公告，近日，公司子公司北京盛迪医药有限公司收到国家药品监督管理局下发的《受理通知书》，公司1类创新药SHR-1918注射液的药品上市许可申请获受理，且已被纳入优先审评程序。SHR-1918注射液是公司自主研发的血管生成素样蛋白3单克隆抗体，通过抑制ANGPTL3的活性，从而降低血清中的甘油三酯和LDL-C水平。经查询EvaluatePharma数据库，该产品2025年全球销售额约为2.16亿美元。截至目前，SHR-1918注射液相关项目累计研发投入约24,220万元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1406674.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0060","BK0196","LU0359201612.USD","LU1997244956.HKD","BK0183","LU2580892862.HKD","01276","LU2495084118.USD","600276","LU0405327148.USD","06978","LU1064130708.USD","LU1655091616.SGD","LU1969619763.USD","LU1328615791.USD","LU0359201885.HKD","BK0188","LU2097828557.USD","LU1820825898.SGD","LU1997245177.USD","LU2580892789.USD","LU1997245094.SGD","BK1574","LU1064131003.USD","LU2097828714.EUR","LU1146622755.USD","BK0012","LU0405327494.USD","LU2097828631.EUR","LU2488822045.USD","159992","LU1023057109.AUD","LU2097828805.USD","LU2543165471.USD","BK1191","LU2289578879.USD","LU1781817850.SGD","LU1580142542.USD","LU2148510915.USD","BK0028","BK1161","LU0359202008.SGD","LU1255011170.USD","LU2328871848.SGD","LU2097828474.EUR"],"gpt_icon":0},{"id":"2614771395","title":"盈利上行但现金流告急，CRO新秀博纳西亚能否“后来居上”？","url":"https://stock-news.laohu8.com/highlight/detail?id=2614771395","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614771395?lang=zh_cn&edition=full","pubTime":"2026-02-24 14:59","pubTimestamp":1771916373,"startTime":"0","endTime":"0","summary":"2025年业绩回暖 毛利率稳步上行财务数据显示，博纳西亚的业绩在经历2024年的短暂回调后，于2025年重回增长轨道。据招股书披露，就2024年来自临床CRO服务的收入而言，博纳西亚在总部位于中国的市场参与者中排名第14位，市场份额为0.7%。现金流压力较大，或是公司急于上市补血的重要原因。整体来看，博纳西亚细分赛道布局清晰，走的是“小而美”的专家路线。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224150431a4c1d5a2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224150431a4c1d5a2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03347","BK1161","BK1576","BK1141","BK1583","BK1574","06978"],"gpt_icon":0},{"id":"2614746805","title":"【券商聚焦】海通国际：香港医疗板块情绪回暖 看好创新药龙头信达生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2614746805","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614746805?lang=zh_cn&edition=full","pubTime":"2026-02-24 11:29","pubTimestamp":1771903764,"startTime":"0","endTime":"0","summary":"金吾财讯|海通国际发布研报指，香港医疗保健板块本周表现强劲，恒生医疗保健指数上涨3.2%，跑赢恒生指数3.2个百分点。板块回暖主要受信达生物与礼来达成88.5亿美元战略合作催化，该交易创下中国创新药企BD新纪录。信达生物将获得3.5亿美元首付款及最高85亿美元里程碑付款，保留大中华区权益，凸显其研发能力获国际认可。海通国际维持对信达生物、药明生物等创新药产业链龙头的\"优于大市\"评级，认为中国创新药企全球化能力持续提升。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224114823a4c13dac&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224114823a4c13dac&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000165453.HKD","BK1574","02252","BK1161","LU2488822045.USD","LU0455707207.USD","LU2097828714.EUR","LU1969619763.USD","02269","LU2097828805.USD","06978","BK1589","LU0502904849.HKD","LU2328871848.SGD","BK1583","LU2242644610.SGD","BK1617","01801","LU2097828474.EUR","BK1100","LU2097828631.EUR","LU2097828557.USD"],"gpt_icon":0},{"id":"2613771023","title":"再加码，中国生物制药1类创新药迎来新进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2613771023","media":"北京药研汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613771023?lang=zh_cn&edition=full","pubTime":"2026-02-24 08:00","pubTimestamp":1771891219,"startTime":"0","endTime":"0","summary":"近日，2026年2月14日，据中国国家药品审评中心官网显示，中国生物制药旗下北京泰德制药股份有限公司按化药注册分类1类申报的TCR1672缓释片临床试验申请获默示许可。此次，TCR1672缓释片获批临床，可谓是该款新药从普通片到缓释片的再加码。P2X3受体在神经系统和呼吸系统中广泛表达，与慢性咳嗽等疾病密切相关。希望北京泰德制药的TCR1672缓释片后续相关临床试验顺利推进，早日为广大患者提供更多的治疗选择。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224081918a7175cac&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224081918a7175cac&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1589","HK0000165453.HKD","BK1515","IE00BZ08YS42.EUR","06978","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","BK1161","01177","BK1521","BK1191"],"gpt_icon":0},{"id":"2612781204","title":"创新药BD热潮今年有望持续：肿瘤、代谢等多个领域有潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=2612781204","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2612781204?lang=zh_cn&edition=full","pubTime":"2026-02-19 08:14","pubTimestamp":1771460083,"startTime":"0","endTime":"0","summary":"2025年中国创新药的BD（业务拓展）出海引爆全球医药行业，2026年这一趋势有望持续。根据国家药监局此前公布的数据，2025年，中国创新药对外授权交易总金额超过1300亿美元，授权交易数量超过150笔，创历史新高。BD热潮在2026年仍在持续，2026年前两个月已经有多笔BD官宣。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602193651489010.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602193651489010.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159992","BK1574","06978","BK1161"],"gpt_icon":0},{"id":"2612551224","title":"创新药出海刷新纪录！开年BD总额超300亿美元 “中国研发效率”备受看好","url":"https://stock-news.laohu8.com/highlight/detail?id=2612551224","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2612551224?lang=zh_cn&edition=full","pubTime":"2026-02-17 18:28","pubTimestamp":1771324119,"startTime":"0","endTime":"0","summary":"2026年以重磅BD强势开年，年初License-out交易首付款总额已超2025年的39%；","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20260217/20260217182931_99455.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260217/20260217182931_99455.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1405810.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["06978","159992","BK1161","BK1574"],"gpt_icon":0},{"id":"2611719421","title":"永泰生物-B完成发行新可换股债券及票据","url":"https://stock-news.laohu8.com/highlight/detail?id=2611719421","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611719421?lang=zh_cn&edition=full","pubTime":"2026-02-16 08:07","pubTimestamp":1771200420,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　永泰生物-B（06978）发布公告，认购协议项下所有先决条件已获达成或豁免（倘适用），且本金总额为人民币2.7亿元的新可换股债券及本金额为人民币3000万元的票据已根据其条款及条件发行予投资者。于本公告日期，认购事项的代价已专门用作全数及最终清偿将于2026年2月20日到期的2023年可换股债券的本金额。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-02-16/doc-inhmyeev7568459.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06978","BK1574","BK1161"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.eaal.net","stockEarnings":[{"period":"1week","weight":0.0709},{"period":"1month","weight":0.0543},{"period":"3month","weight":-0.1023},{"period":"6month","weight":-0.4839},{"period":"1year","weight":-0.4799},{"period":"ytd","weight":-0.0717}],"compareEarnings":[{"period":"1week","weight":-0.0122},{"period":"1month","weight":-0.0275},{"period":"3month","weight":0.0202},{"period":"6month","weight":0.052},{"period":"1year","weight":0.109},{"period":"ytd","weight":0.0293}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"永泰生物制药有限公司是一家主要从事用于治疗癌症的细胞免疫产品的研发、制造及商业化的投资控股公司。该公司的非转基因细胞产品管线包括扩增活化淋巴细胞（EAL）和6B11-OCIK注射液。该公司的嵌合抗原受体T（CAR-T）细胞产品管线包括CAR-T-19注射液、迪诺仑赛注射液和aT19注射液。该公司的T细胞受体工程化T细胞疗法（TCR-T）细胞产品管线包括YT003、YT008及YT007。该公司主要在中国市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.074078},{"month":2,"riseRate":0.666667,"avgChangeRate":0.180355},{"month":3,"riseRate":0.4,"avgChangeRate":-0.092735},{"month":4,"riseRate":0.2,"avgChangeRate":-0.078794},{"month":5,"riseRate":0.4,"avgChangeRate":-0.038349},{"month":6,"riseRate":0.8,"avgChangeRate":0.080731},{"month":7,"riseRate":0.2,"avgChangeRate":-0.000149},{"month":8,"riseRate":0.5,"avgChangeRate":0.012587},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.035807},{"month":10,"riseRate":0.5,"avgChangeRate":-0.057833},{"month":11,"riseRate":0.5,"avgChangeRate":0.001253},{"month":12,"riseRate":0.666667,"avgChangeRate":0.067669}],"exchange":"SEHK","name":"永泰生物-B","nameEN":"IMMUNOTECH-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供永泰生物-B(06978)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"永泰生物-B,06978,永泰生物-B股票,永泰生物-B股票老虎,永泰生物-B股票老虎国际,永泰生物-B行情,永泰生物-B股票行情,永泰生物-B股价,永泰生物-B股市,永泰生物-B股票价格,永泰生物-B股票交易,永泰生物-B股票购买,永泰生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供永泰生物-B(06978)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}